Your Health, We Care
Another NameCaprelsa、凡德他尼
IndicationsIndicated for the treatment of unresectable, locally advanced or metastatic, symptomatic or progressive medullary thyroid cancer (MTC).
Specs
Telegram name: Vira
Name: LUCIUS
No.:0085253923643
Vandetanib was first approved in the United States in 2011, and the latest revision of its prescribing information was in May 2025.
Indicated for adult patients with confirmed unresectable locally advanced or metastatic medullary thyroid cancer.
The standard recommended dose is 300 mg orally once daily, with or without food; dosage adjustment may be required based on toxicity or the patient's renal function. Reference article: Dosage and Administration of Vandetanib
The starting dose requires adjustment in patients with moderate renal impairment; it is not recommended for patients with severe hepatic or renal impairment; men and women of reproductive potential, pregnant women, and breastfeeding women must strictly observe contraception and breastfeeding restrictions.
In case of overdose, closely monitor the QTc interval on electrocardiogram, as its long half-life may prolong the effects.
The drug is slowly absorbed after oral administration, has a long half-life of approximately 19 days, and steady-state plasma concentrations are reached in about 3 months; it is primarily excreted slowly in feces and urine.
Telegram name: Vira
Name: LUCIUS
No.:0085253923643
